Boron nitride nanomaterials: Biocompatibility and bio-applications by Merlo, A. et al.
Boron nitride nanomaterials: Biocompatibility and bio-applications
Downloaded from: https://research.chalmers.se, 2019-05-11 18:35 UTC
Citation for the original published paper (version of record):
Merlo, A., Mokkapati, V., Pandit, S. et al (2018)
Boron nitride nanomaterials: Biocompatibility and bio-applications
Biomaterials Science, 6(9): 2298-2311
http://dx.doi.org/10.1039/c8bm00516h
N.B. When citing this work, cite the original published paper.
research.chalmers.se offers the possibility of retrieving research publications produced at Chalmers University of Technology.
It covers all kind of research output: articles, dissertations, conference papers, reports etc. since 2004.
research.chalmers.se is administrated and maintained by Chalmers Library
(article starts on next page)
Biomaterials
Science
REVIEW
Cite this: Biomater. Sci., 2018, 6,
2298
Received 8th May 2018,
Accepted 18th July 2018
DOI: 10.1039/c8bm00516h
rsc.li/biomaterials-science
Boron nitride nanomaterials: biocompatibility and
bio-applications
A. Merlo,a V. R. S. S. Mokkapati, b S. Panditb and I. Mijakovic*b
Boron nitride has structural characteristics similar to carbon 2D materials (graphene and its derivatives)
and its layered structure has been exploited to form diﬀerent nanostructures such as nanohorns, nano-
tubes, nanoparticles and nanosheets. Unlike graphene and other carbon based 2D materials, boron nitride
has a higher chemical stability. Owing to these properties, boron nitride has been used in diﬀerent appli-
cations as a ﬁller, lubricant and as a protective coating. Boron nitride has also been applied in the biomedical
ﬁeld to some extent, but far less than other 2D carbon materials. This review explores the potential of boron
nitride for biomedical applications where the focus is on boron nitride biocompatibility in vivo and in vitro,
its applicability as a coating material/composite and its anti-bacterial properties. Geometry, material proces-
sing and the type of biological analysis appear to be relevant parameters in assessing boron nitride
bio-compatibility. Engineering of both these variables and the coating would open the door for some appli-
cations in the medical ﬁeld for boron nitride, such as drug delivery, imaging and cell stimulation.
Introduction
Boron nitride (BN) is a refractory material made of boron and
nitrogen. It can crystallize in diﬀerent forms depending on
pressure and temperature1,2 (hexagonal, rhomboedral,
diamond-like cubic3 and wurzite4), but its most stable form at
room temperature is the hexagonal form. This configuration is
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characterized by the disposition in layers of hexagons of alter-
nating boron and nitrogen atoms, similar to graphene struc-
ture. The hexagonal layer plane features strong covalent bonds
with a spacing almost identical to that in graphene. The layers
forming the three-dimensional structure are kept together
through van der Waals forces, as B and N atoms align alter-
nately in a vertical direction, as described in ref. 5. Owing to
structural characteristics very similar to graphene, this
material attracted increasing attention in recent years, as its
layered structure was exploited to form diﬀerent nano-
structures such as boron nitride nanotubes, nanosheets, nano-
horns and nanoparticles with diﬀerent shapes.4
While structurally very similar to its carbon counterpart, BN
is characterized by specific and unique properties which rep-
resent a considerable advantage in some specific applications.
Unlike graphene, whose band gap depends on chirality and
diameter, BN has a consistent gap of 5.5–6 eV6,7 when reduced
from bulk to layer form. Unique mechanical properties8–11 and
thermal conductivity,12,13 combined with a remarkable anti
oxidation capacity14 of BN could be exploited to enhance pro-
perties of various composites. While the addition of carbon
nanostructures to polymers may compromise the electrical
insulation, in the case of BN the dielectric properties would be
retained. Compared to its carbon-based counterparts which
are colored (mostly black), BN is white colored and would
allow dying, which might be of interest in the medical field.
Its optical properties are applicable in the UV-regime, which
distinguishes it from carbon nanotubes that absorb in the IR
range. Finally, BN was found to possess remarkable piezoelec-
tric properties,15 a feature that opened up new scenarios for
innovative applications.
BN is chemically more stable than carbon nanomaterials
and so to improve the dispersibility in aqueous solutions,
surfactants are often used.16 Surfactants are rather used in two
diﬀerent ways in the case of BN: (1) as co-solvents during exfo-
liation17,18 of BN nanosheets and (2) for direct dispersion.19
Given these distinctive dispersion parameters, BN has thus far
been used in many diﬀerent fields for diﬀerent goals: as a
filler in composites to improve both mechanical20 and thermal
properties, as a lubricant21 for protective coatings22–25 in cos-
metic products,26 and also for hydrogen storage.27,28
Considering the analogy with the carbon structures to
which BN is very similar, this material has attracted a consider-
able interest in the biomedical field in the recent years.
Nevertheless, its use in biomedical applications is still lagging
behind that of carbon structures.
Employment of carbon nanostructures, especially carbon
nanotubes, has been investigated in biosensing, imaging and
cancer cell targeting, but the debated degree of cytotoxicity of
these carbon nanomaterials29–31 has opened up venues for
developing alternative, non-toxic solutions and materials. In
fact, while functionalization may limit the cytotoxicity of the
material, the possibility of in situ desorption does not comple-
tely eliminate the toxic eﬀects. The superior chemical inert-
ness of BN with respect to carbon nanostructures constitutes a
strong argument for using this material as a replacement of
carbon nanostructures in biomedical applications.
Biocompatibility in vitro
In 2008, Chen et al. reported compatibility of BN nanotubes
with kidney cells.32 These nanotubes are tubular with a struc-
ture analogous to that of carbon nanotubes. The multi walled
BN nanotubes in this study were produced through CVD
(Chemical Vapor Deposition) process33 to obtain finals lengths
of up to 10 mm, and outer diameters around 20 nm (Fig. 1).
These nanotubes, without any functionalization (concentration
of 100 mg mL−1) were tested on kidney cells and shown to not
exhibit any cytotoxicity. Further, these nanotubes were coated
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with glycodendrimer, which was engineered in order to bind
specifically to the cell surface. The coated BNNTs were also not
toxic.34 As stated above, without any functionalization these
nanotubes are likely to aggregate, and that would necessarily
impact the results of compatibility assays. If the same kidney
cells were to be probed with non-aggregated nanotubes, given
the shape, aspect ratio and active surface, the results might
vary. Therefore, further studies are needed to assess the bio-
compatibility of non-aggregated BNNTs.
Horváth et al. reported the cytotoxicity of BNNTs and
proved that the toxicity is a function of both time of exposure
and concentration.36 In this study, multi-walled BNNTs, with
an average length of 10 µm were produced by CVD, followed by
secondary treatments such as high temperature annealing in
Ar and acid washing. The nanotubes in solution, de-aggregated
thanks to the use of a biocompatible surfactant, were then
tested on human lung adenocarcinoma epithelial cells,
human embryonic kidney cells, murine embryonic fibroblast
cells and murine alveolar macrophage cells in diﬀerent con-
centrations. Toxic eﬀects were visible already after 48 h com-
pared to controls, with a marked dependence not only on the
time of exposure and concentration, but also on the cell line
examined. Higher concentration and time of exposure led to
lower cell viability, combined with a change in morphology
and metabolism (Fig. 2).
In accord with previous results obtained on CNTs,37 toxic
eﬀects were most severe for macrophage cells, while the kidney
cells were most resistant. This suggested that cytotoxicity
might be related to the predisposition to phagocytosis of the
tested cells, i.e. their natural capacity to internalize nanotubes.
The reported cytotoxicity of BNNTs towards kidney cells31 was
much higher compared to the BNNTs toxicity reported in a
previous report on the same kind of cells.32
The study of Horváth et al.36 emphasized the necessity of
ulterior research on the biocompatibility of boron nitride
nanostructures, pointing out that diﬀerent factors aﬀect their
interaction with cells.
Ciofani et al.38 conducted cytotoxicity tests on multi-walled
BNNTs produced with the same method used by Horváth
et al.,36 but shortened to an average length of 1.5 µm. The
length diﬀerence led to very diﬀerent results on bio-compat-
ibility. In this case, gum arabic was used to disperse and
stabilize the nanotubes suspension, which was tested on
neuroblastoma cells and human umbilical vein epithelial cells
with progressively increasing concentrations from 0 to 100
µg mL−1, for up to 72 h. While doses of 50 and 100 µg mL−1
proved to be toxic towards both kind of cells; concentrations of
up to 20 µg mL−1 did not indicate any adverse eﬀect on cell
metabolism or in cell morphology after 24 h. No change of
neuroblastoma cells diﬀerentiation was observed (Fig. 3).
Fluorescence analysis for detection of reactive oxygen
species in the epithelial line showed no relevant sign of oxi-
dative stress up until 48 h. TEM observations on epithelial
cells established that the morphology and shape of the nano-
tubes, once phagocytised, did not change. Their spatial orien-
tation when internalized was random, and they were always in
the cytoplasm, never in the nuclei. According to these obser-
vations, the display of cytotoxicity in previous reports36 may
have been influenced by the dimensions of the nanotubes
used, in line with some previous observations on carbon nano-
tubes toxicity on cells.39
In an attempt to evaluate the toxicity of BN on cells, Ciofani
et al. came to an interesting result concerning cell viability
measured trough MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium bromide) assays40 that are extensively used
to evaluate biocompatibility. In this study, BNNTs were
obtained through a self-propagation, high-temperature syn-
thesis process.41 After 48 hours of incubation with human
neuroblastoma cells, the MTT assay revealed a significant MTT
decrement for concentrations around 20 µg mL−1. This finding
Fig. 2 LIVE/DEAD® viability/cytotoxicity assay and early apoptotic
detection (annexin V-FITC/PI assay) performed for diﬀerent incubation
times and concentrations. Note: Scale bar: 100 μm. Reproduced with
permission from Int. J. Nanomed., 2010, 5, 285–298. Copyright 2010
Dove press.35
Fig. 1 Structural characterization of pristine multiwalled BNNTs with
high purity and high quality. (a) The SEM image of BNNTs. (b) High
resolution TEM image of a BNNT. Reproduced with permission from
J. Am. Chem. Soc., 2009, 131, 890–891. Copyright 2008 ACS.32
Review Biomaterials Science
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was in contrast to microscopic observations of diﬀerent cell
cultures treated in the same way for the same amount of time.
Both treated and untreated cells did not show any significant
diﬀerence in cellular density or morphology. The use of
diﬀerent assays allowed to highlight an interference with the
MTT assay, especially for high concentrations of boron nitride
particles, that resulted in false results about elevated cyto-
toxicity. In fact, as observed under the microscope, cell viabi-
lity decreased with respect to controls only at concentrations
superior to 50 µg mL−1, and cell proliferation was non-
impacted. In turn, this proved that even at concentrations as
high as 100 µg mL−1, boron nitride particles would still be bio-
compatible, and the toxicity results obtained with the MTT
assay are to be interpreted with caution(Fig. 4 and 5).
Mateti et al.42 reported another interesting observation on
the biocompatibility of boron nitride nanosheets. They pro-
duced nanoparticles in diﬀerent dimensions through a
process of ball milling in argon, and ammonia for nanosheets
in order to allow the exfoliation of sheets.43 The time spent in
the mill and the dimension of the final product were inversely
proportional (the precursor powders used for the milling
process had a dimension of 15 µm for around 2 µm in thick-
ness). The process delivered nanoparticles with a spherical
shape and a diameter range of 100 to 200 nm. Two major sub-
groups of nanosheets were identified, one with an average dia-
meter of 1 µm for 100 nm in thickness, while the second
group had a diameter of around 100 nm and 3 nm in thick-
ness. The tests on cell viability of human osteosarcoma cells
conducted in the presence of the material in its diﬀerent
shapes and forms indicated a progressive decrease in biocom-
patibility with the decrement of the size of both the particles
and nanosheets.
The cell viability tests were backed up by light microscopy
images. From the analysis of elemental composition of the cel-
lular culture media used to test the toxicity of increasing con-
centrations of material, it was evident that there was signifi-
cant change in boron content (Fig. 6 and 7).
Fig. 3 Cytopathological analyses of HEK293 kidney cells (ﬁrst row),
A549 epithelial cells (second row), 3 T3-L1 ﬁbro-blasts (third row), and
RAW 264.7 macrophages (fourth row) not treated with ENMs (control,
ﬁrst column) and treated for 4 days with approximately 2 μg mL−1 of
p-CNT (second column), f-CNT (third column), and BNNT (fourth
column). BNNT-treated RAW 264.7 and 3 T3-L1 cells revealed character-
istic alterations in morphology. These included disrupted cell to cell
contacts leading to a more rounded appearance, due to cell retraction
(eosinophilia). Consequently, the cytoplasmic staining was stronger (red
circles), and cells with picnotic nuclei were present (red arrows). In
addition, large multinucleated cells (black circles) undergoing frustrated
phagocytosis were observed in the RAW 264.7 macrophages. Scale bars
are 50 μm. Reproduced with permission from ACS Nano, 2011, 5,
3800–3810. Copyright 2011 ACS.36
Fig. 4 Cytocompatibility evaluation on SH-SY5Y cells. (A) WST-1 assay
results on cultures treated with 0–100 μg ml−1 of BNNTs for 24, 48 and
72 h; (B) Live/Dead® staining performed after 72 h of treatment.
Reproduced with permission from Nanomedicine, 2014, 9, 773–788.
Copyright 2014 Future Medicine.38
Fig. 5 Boron nitride nanotube uptake investigation. (A) Low- and (B)
high-magniﬁcation transmission electron microscopy images of boron
nitride nanotubes internalized by human umbilical vein endothelial cells.
Electron diﬀraction analysis of boron nitride nanotubes showed in the
inset of (A). Reproduced with permission from Nanomedicine, 2014, 9,
773–788. Copyright 2014 Future Medicine.38
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Higher surface area would suggest more unsaturated boron
atoms on the surface, whose high reactivity would induce the
production of ROS species and explain the increasing toxicity
for decreasing particle dimensions. An alternative reason
suggested by the authors was that smaller nanoparticles are
more eﬀectively imported on the cells by phagocytosis, and
then trigger the ROS formation. Irrespective of the type of
mechanism by which nanoparticles act, this study further sup-
ports the notion that the size and shape of the boron nitride
nanoparticles have a strong impact on its biocompatibility, in
accord with,36,38,39 this would also explain why similar sizes
for diﬀerent shapes induce diﬀerent responses in the tested
cells, as could be noticed for the dimension of the nanosheets
in this study and that of nanotubes in previous reports, where
the material was found to be biocompatible, thanks to a lower
number of unsaturated B atoms.
Wetting/non-wetting behaviour of BN
As it has been realized from the literature that BN itself is
fairly bio-compatible, the reported toxicity is arising from the
coatings that are introduced on BN. This section describes the
importance and eﬀect of coatings on BN towards mammalian
cells. Prior to this, it is worth mentioning that the wetting pro-
perties of BN play an important role in characterizing and
identifying the appropriate coating material, which in turn
plays an important role in performance. Like graphene, BN is
weakly hydrophobic with a contact angle of 86°.44
Interestingly, the BN contact angle range varies with the syn-
thesis temperature.45 This property of flexible tailoring during
growth gives the feasibility to have BN nanosheets ranging
from hydrophilic to super hydrophobic. In 2009, it was
reported that partially vertically aligned BNNTs grown on
silicon substrates are superhydrophobic compared to BN thin
films.46 Amir Pakdel et al., have reported that the synthesis
temperature range is directly proportional to the increase in
contact angle. For synthesis temperatures of 900 °C to 1200 °C
the reported contacted angles are in the range of 50° to 150°,
respectively. The same authors in their next work have
reported the tailoring of BN nanosheets from super hydro-
philic to hydrophobic.47 Interestingly, they have used pre-
viously synthesized superhydrophobic BN nanosheets (ref
above) and films and altered their surface wetting properties
by a one-step plasma process leading to grafting of functional
groups (hydroxyl). This process not only makes it easier to
determine the surface properties of BN sheets but also solves
the dispersibility issues that were faced by many researchers.
Similar works have been reported by several researchers which
explains the wetting and non-wetting properties of BN
films.48–52
Importance of a coating
To the best of our knowledge, BN biocompatibility was first
investigated by Ciofani et al. in 200853,54 with an evaluation of
the impact of polyethyleneimine-wrapped boron nitride nano-
tubes (BNNTs) on neuroblastoma cells. The BNNTs, produced
through ball milling and annealing,55 were first coated with a
polymer to attain a stable dispersion in aqueous suspension,
and then tested with cells for up to 72 hours. Cell viability and
replication retained relatively normal values up to a PEI-
coated-BNNTs concentration of 5.0 µg mL−1, and then
decreased to around 75% after 72 h. This shift was attributed
to the coating, but not to the material itself. Cellular uptake of
quantum dots attached to these nanotubes by endocytosis did
not seem to have negative eﬀects on cell function and mor-
phology. Rather, the energy-dependent pathway identified for
the nanotubes internalization might again be due to the PEI
coating, rather than nanotubes itself.
Fig. 7 Bright-ﬁeld microscopy images of SaOS2 cells cultured in the
presence of (a) standard culture medium (control), (b) bulk BN, (c)
nanosheet NS1, (d) nanosheet NS2, (e) nanoparticle NP1, and (f ) nano-
particle NP2. Reproduced with permission from Nano Res., 2017, 11,
334–342 Copyright 2017 Springer.42
Fig. 6 Percentage cell viability of SaOS2 cells, as measured by MTS
assay on commercial BN, BN nanoparticles, and BN nanosheets.
Reproduced with permission from Nano Res., 2017, 11, 334–342
Copyright 2017 Springer.42
Review Biomaterials Science
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In order to guarantee the dispersion of nano-dimension
boron nitride compounds and avoid subsequent clustering
caused by the natural hydrophobicity of the raw material, coat-
ings are necessary. In fact, as proven in the case of carbon
nanotubes, cytocompatibility results might depend not only
on the material but also on the processing and final shape of
the compound, where the latter would be strongly impacted in
case of agglomeration. Based on their previous results, Ciofani
et al.35 suggested the use of BNNTs coated with poly-L-lysine
(PLL) and investigated its interaction with C2C12 cells. BNNTs
were produced through ball milling and annealing, to obtain
nanotubes with an average length of 242 nm. As expected,
these were dispersed in a stable aqueous solution using PLL.
Conjugated quantum dots allowed the tracking of the material
into the living cells. Overall, the cell viability and cell density
were not diﬀerent from the control, regardless of the concen-
tration of PLL-BNNT tested. The achievement of confluence in
all performed tests suggested that BNNT did not have any con-
siderable impact on cellular replication. Interestingly, decrease
in metabolic activity was observed when the cells were incu-
bated with 3 µg mL−1 solution of PLL only, suggesting that the
surfactant may be toxic to some extent. With lower concen-
trations of PLL-coated-BNNTs, no significant membrane
damage was observed in the cells, and a comparable to slightly
increased value in protein content could be observed for cells
undergoing diﬀerentiation. Through the combined use of
quantum dots and sodium azide, it was possible to conclude
that the mechanism of internalization of the nanotubes was
energy-dependent.
As previously stated, the intrinsic inertness of BN com-
pounds, in any shape, determines high hydrophobicity of the
material and makes it diﬃcult to disperse. This distinctive
trait might strongly impact the results of biocompatibility
assays both in vitro and in vivo, and this limitation needs to be
overcome. Adoption of specific solutions such as surface
coating and functionalization, both with covalent and non-
covalent possibilities, can help in enhancing dispersion. This
in turn would permit to exploit the better stability and surface
zeta potential of BN in solution, both of which may impact the
compatibility and internalization of the material.56,57
For example, Li et al.58 coated BNNTs with silica in order to
improve the stability of the suspension and to increase the
loading and delivering eﬃciency of doxorubicin by controlling
the surface zeta potential of the material. In this study, BNNTs
were synthetized through CVD process33 followed by oxidation
and sonication to reduce the original size to around 1 µm.
This resulted in a stable suspension after 24 h, while the non-
coated control sedimented after 3 h. After this, doxorubicin
was loaded on both functionalized and non-functionalized
BNNTs, to test how the loading and endocytosis eﬃciency
changed with surface charge. Given that higher stability of the
suspension enhances the uptake by cells, as does the positive
surface charge of the particle, BNNTs functionalized with
nanoporous silica with NH2 grafted on the surface proved to
be a valid engineered tool for drug delivery into cells. They
yielded superior results compared to simple mesoporous silica
functionalized BNNTs (stable but with a negative zeta poten-
tial) and non-functionalized BNNTs. Ulterior confirmation of
these results was obtained by an in vitro study on prostate
cancer cells that delivered confirmatory results. In conclusion,
the coating did not only fulfill its original goal of improving
the suspension stability, but actually played a key role in
improving the drug loading ability and delivery eﬃciency.
Nithya et al.59 confirmed that coating eﬀectively helps with
the suspension stability and can also be used to confer specific
characteristics to BNNTs. In addition, the coating had an
impact the final compatibility of the material.55 In the cited
article, the cytotoxicity of BNNTs coated with diﬀerent poly-
mers was examined. Specifically, the eﬀect of pluronic P123,
pluronic F127, polyethileneimine and ammonium oleate coat-
ings of nanotubes were examined on Vero and Chang cells,
breast cancer cells and adenocarcinomic human alveolar basal
epithelial cells.
A preliminary test revealed high toxicity of PEI starting from
low concentrations. For the other polymers, the cell viability
decreased to around 20% with increasing polymer concen-
tration, with the notable exception of pluoronic F127 that was
far less toxic, even at concentrations as high as 1 mg mL−1. The
nanotubes were then coated with the four diﬀerent polymers
and incubated for 24 h with the cells. Again, pluronic F127 was
most bio-compatible, while PEI was most toxic. Interestingly,
while both the pristine and pluronic F127 coated nanotubes
were not toxic at concentrations lower than 250 µg mL−1, once
loaded with anti-cancer drugs, a 50% death of cancerous cells
was attained with nanotube concentrations lower than those
necessary to free anticancer drugs to obtain the same results.
The authors concluded34 that even in case of biocompatible sur-
factants, as pluronic F127, pristine BNNTs do show a certain
level of cytotoxicity above the concentration of 250 µg mL−1,
and the surfactant shielding action is not eﬀective in limiting
the nanotubes toxicity above that concentration. In drug delivery
applications drug-loaded BNNTs proved to have better eﬃcacy
compared to the administration of free drug.
Another way to remedy the hydrophobicity of BN may be to
find alternative processing methods or subsequent treatments
to make the material less hydrophobic, or even hydrophilic,
thus allowing a better dispersion in solution. In this regard,
an interesting example is provided by Li et al.,60 regarding
wettability of BNNT film. The said films were grown on sub-
strates of steel using the boron ink method,61 to a final thick-
ness of 20–40 µm. The films then underwent a N2 + H2 gas
plasma treatment using diﬀerent modes, in order to impact
the material surface. This changed the contact angle of the
material from the original 158 degrees to a range from 60 to 5,
according to diﬀerent modes of plasma treatment, thus
making the final product hydrophilic to super hydrophilic. In
particular, the treatment with a conjugation of pulsed and con-
tinuous wave plasma led to a higher quantity of N-containing
functional groups on the film surface. This, in turn, correlated
with enhanced cell proliferation and viability of both human
mammary fibroblast and transformed cell line tested on the
BNNT samples (Fig. 8).
Biomaterials Science Review
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A diﬀerent approach aimed at improving the stability of
boron nitride nanoparticles suspension was adopted by Weng
et al.62 In this study, BNs were obtained through an innovative
solid reaction, where boric acid substructures substitute C
atoms in graphitic carbon nitride thanks to a thermally acti-
vated process. This new processing method considerably
increases the number of hydroxylic groups on the surface, and
allows the formation of a stable water solution with boron
nitrides up to a concentration of 2 mg mL−1, without the need
for any surfactant.
The testing of boron nitride nanoparticles biocompatibility
with mouse embryonic fibroblast cells and human prostate
cancerous cells showed no adverse eﬀect on either of the cell
lines, with a viability superior to 90% for all concentrations
tested up to 100 µg mL−1. Nanotubes loaded with doxorubicin
were tested on human cancerous cells to evaluate the transport
properties of drugs in vitro: results showed a loading capacity
dependent on the duration of the solubilization treatment. In
addition, higher toxicity on cancerous cells in case of
DOX wrapped with hydroxylated BNs with respect to free
doxorubicin was observed, presenting the final product as a
good candidate for drug delivery applications.
Applications in composites
Superior mechanical properties of BN nanotubes have led to
their use in a number of composites. A very common use of
BN nanostructure/compounds has been as a reinforcing phase
in composites, some of which with biomedical applications.
This necessitated an investigation of cytotoxicity of the compo-
sites enhanced by BNNTs.63,64
In 2010, Lahiri et al. designed a biodegradable polylactide-
polycaprolactone copolymer reinforced with BNNTs to be
employed as a scaﬀold in tissue engineering.65 Given the bio-
degradability of the matrix, it is extremely relevant that the
reinforcing phase is biocompatible, considering the long-time
permanence of the scaﬀold in the tissues. In this study, the
NTs had a final length ranging from 0.43 to 5.8 µm and a
mean diameter of 71 nm. In addition to a noteworthy enhance-
ment of both tensile strength and elongation, cytotoxic ana-
lysis on osteoblasts and macrophages did not underline any
remarkable cytotoxic eﬀect. On the contrary, BNNTs addiction
to the matrix granted a change in osteoblast cell morphology,
slightly more lens shaped, and accelerated growth and diﬀer-
entiation. The authors argued that this eﬀect was due to the
natural aﬃnity of BNNT for proteins. A similar approach was
adopted by Lahiri et al. in a subsequent study,66 where BNNTs
were used to reinforce hydroxyapatite (HA). In this case,
BNNTs had a length ranging from 0.43 to 5.8 µm and a mean
diameter of 71 nm, with slightly diﬀerent shapes. This time
the composite was obtained through spark plasma sintering,
after a homogenous mixing of the precursor powders through
ultrasonication. The viability of osteoblasts on HA-BNNT did
not noticeably diﬀer from the control of HA only, while pro-
liferation and diﬀerentiation were enhanced. The authors
suggested that this is due to the natural aﬃnity of BNNTs
toward proteins, whose attachment on the BNNTs surface
might assist the proliferation of osteoblasts.
In addition to the mentioned mechanical properties, used
for strengthening composites, the piezoelectric behaviour of
BN nanotubes means they could be used for cell stimulation.
Ciofani et al.67 examined the eﬀects of BNNT nanovectors on
neuronal-like cells. In this study, NTs of 200–600 nm in
length41 were dispersed with glycol-chitosan, which provided a
non-covalent wrapping of the material to permit a better stabi-
lity of the suspension. A preliminary test conducted to evaluate
the biocompatibility of the material showed no diﬀerence in
cell viability compared to controls up to concentrations of
50 µg mL−1. Until the 9th day of exposition, there was no sign
of ROS formation, apoptosis, nor any relevant change in terms
of cellular diﬀerentiation. TEM imaging confirmed previous
observations of nanotubes internalized in the cytoplasm and
contained in vesicles. When nanotubes underwent ultra sound
stimulation, thus expressing their piezoelectric behaviour,
cells were electrically stimulated. This led to an increase in the
number and length of neurites, and in the number of neuronal
processes per diﬀerentiated cell.
Danti et al.68 investigated the interactions of BN nanotubes
with human mesenchymal cells of diﬀerent origins. In
addition to the absence of relevant toxicity on the cells, TEM
images confirmed the phagocytosis of the material inside the
cell cytoplasm. These findings were further corroborated by a
later study by the same group,69 where BNNTs taken up by
osteoblast cells were stimulated through low frequency ultra-
sounds. BNNTs with a length inferior to 500 nm were obtained
through a milling and annealing method70 and coated with
poly-L-lysine in order to attain a stable suspension. To test cell
viability and define the optimal concentration that would
combine least toxicity with eﬀective cell stimulation, media
containing PLL-coated BN nanotubes in various concen-
trations were incubated with human osteoblastic cells up to
three days. No cytotoxicity, apoptosis or necrosis was detected,
Fig. 8 SEM images of ﬁbroblasts on (a) untreated and (b and c) plasma
treated BNNT ﬁlms; and TXP RFP3 cells on (d) untreated and (e and f)
plasma treated BNNT ﬁlms. Scale bars: (a and b) 50 μm; (c) 5 μm; (d and
e) 20 μm; (f ) 5 μm. Reproduced with permission from J. Phys. Chem. C,
2012, 116, 18334–18339. Copyright 2012 ACS.60
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and a concentration of 10 µg mL−1 was found to be optimal.
The presence of BNNTs alone, engulfed by phagocytosis,
seemed to increase the maturation of osteoblasts.
Mineralization of osteoblast was triggered specifically with
ultra sound stimulation. Aside from the improvement of
mechanical properties provided by the use of BN as second
phase and the possibility the exploitation of its piezoelectric
properties open, boron nitride can also be used for other
purposes.
In a study by Li et al.,71 interaction of a BN nanotubes layer
with mesenchymal cells was evaluated. The 2D material was
obtained by chemical vapor deposition,33,72 followed by a sec-
ondary treatment in order to purify and shorten73 the resulting
nanotubes to an average length of around 1–2 µm.
Interestingly, the BNNT layer seemed to improve both cellular
attachment and protein adsorption, and fluorescent analysis
disclosed how cells cultivated in contact with the BN layer had
better attachment and spreading on the surface with respect to
the control on simple glass. In particular, it was observed that
there is an enhanced cell proliferation over the test period for
a concentration of 5 µg mL−1, and a higher secretion of pro-
teins specific for osteogenic diﬀerentiation is identifiable for
the said concentration with respect to the controls over the
same lapse of time (Fig. 9).
Analogously, Farshid et al.74 attempted to construct a poly-
meric matrix composite useful for tissue engineering, with a
reinforcing second phase of BN. Their study was mostly related
to comparing the change in mechanical properties and inter-
action with cells in case of diﬀerent shapes of the material,
specifically nanotubes and nanoplatelets.
To create the composite, polypropylene fumarate, a bio-
degradable polymer with extensive use in biomedical appli-
cations, was mixed with N-vinyl pyrrolidone, a crosslinker, and
0.2% w/w of boron nitride nanoplatelets or nanotubes. The
addition of a second phase increased both the Young`s
modulus and the compressive yield strength compared to the
polymeric control only, particularly in case of addition of NPs,
for which the increase was 38% and 31%, respectively for the
two cited mechanical properties. Raw Polypropylene fumarate
was tested in multiple conditions with boron nitride particles/
platelets concentrations, before and after crosslinking and in
its degradation products within the system.
Overall, the composite showed good biocompatibility, with
a cell viability dependent on the second phase concentration.
The cell viability for raw material dispersions with concen-
trations up to 100 µg mL−1 was above 73%, and it was further
enhanced in the composite form, where the viability rose to
79% and above. In addition, acceptable levels of cellular
attachment and normal cellular morphology were reported.
The toxicity of the degradation products exhibited a dose
dependent behaviour.
Toxicology in vivo
Up to date, in vivo toxicology results on BN are very limited.
Ciofani et al.75 reported the first pilot investigation on BNNTs,
injecting a single dose of 2 mL of solution with a concen-
tration of 1 mg mL−1 of BNNTs coated with G-chitosan in the
marginal ear vein of male rabbits. BNNTs were produced
according to the process already adopted by the same group.41
FIB images show a final length of the nanotubes comprised
between 0.5 and 2.0 µm, and a diameter between 30 and
100 nm. At time points of 0, 2, 4, 24 and 72 hours, blood ana-
lysis was performed and out of ordinary behaviour, such as
sweating and trembling, was monitored. No change in behav-
iour was noticed during the entire period. Blood analysis
values did not diﬀer significantly from those of the controls
injected with chitosan only, with the exception of the platelets
count, which was higher in the presence of BNNTs after 72 h.
The same group reported a follow-up study,76 increasing the
dosage, prolonging the monitoring time to 7 days and testing
possible diﬀerences in case of multiple injections. In this
study, the mean length of the nanotubes was around 500 nm.
Again, no behavioural change was detected for the entire
period of observation, regardless of the dose or the injection
pattern. Blood samples, collected 0, 1, 3 and 7 days after injec-
tion, did not show any significant diﬀerences with respect to
controls. Moreover, a preliminary analysis of the pharmaco-
kinetic behaviour of the material showed a good distribution
in the body, with rapid clearance from the blood. It is unclear
whether this is related to the nanotubes themselves, or the
Fig. 9 Left: Fluorescent images of MSCs after 24 h of culture with
control (A–C) and BNNTs layer at 2 μg mL−1 (D–F); Right: Quantiﬁcation
of cell attachment area of MSCs after 24 h of culture with control and
BNNTs layer at 2 μg mL−1 (n = 80). Reproduced with permission from
J. Biomed. Mater. Res., Part B, 2016, 104, 323–329. Copyright 2016 John
Wiley and Sons.71
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surface coating. If the last assumption was correct, that would
also accord the possibility of controlling the permanence of
the coated nanotubes inside the body with the use of diﬀerent
coatings, in order to best fit the requirements of their eventual
application, may it be short or long-termed.
In the latest report on the topic, Salvetti et al. tested the
compatibility of BNNTs on planarians.77 Multi-walled BNNTS
were fabricated through a CVD process,72 then underwent a
shortening and stabilization process43 to deliver nanotubes
with an average length of 1.5 µm, which were eventually coated
with gum arabic. Diﬀerent doses and number of injections
were chosen in order to evaluate the toxicity in case of acute
and chronic exposures. In this case too, no behavioural change
was detected after the injections. No morphological change or
DNA damage in cells was detected either, and no sign of nano-
tubes was found three days after the last injection. In con-
clusion, BNNTs did not prove to be cytotoxic when tested
in vivo on planarians, while the coating may reduce the poss-
ible toxicity of the raw material. The possible dissolution of
the non-covalent surface coating after the endocytosis, due to
intrinsic inertness, suggests that the raw material itself would
not cause any significant damage. Further investigations are
necessary, since the in vivo trials conducted thus far are only a
starting point.
Antibacterial properties
Antibacterial properties of BN have not been thoroughly inves-
tigated. In the study by Nithya et al.,59 pristine BNNTs and
BNNTs functionalized with diﬀerent kinds of polymers were
tested on Escherichia coli and Staphylococcus aureus. Raw
material did not have any bactericidal eﬀect. The authors
argue that this is due to the intrinsic hydrophobicity of the
nanotubes and weak interactions between OH groups and BN,
which would prevent eﬀective interaction with the bacteria. As
previously observed, pristine PEI exhibited a strong antibacter-
ial eﬀect, while the other tested polymers were harmless to
bacteria.78 When used as coatings, the same pattern emerged
with the tested polymers. No significant decrease in bacterial
optical density was observed for pluronic P123, pluronic F127
and ammonium oleate coated nanotubes, while PEI-coated
BNNTs were bactericidal. From these observations, it can be
concluded that BNNTs do not seem to have inherent bacteri-
cidal eﬀect, and any antibacterial activity observed was due to
the coating. By contrast, according to the research conducted
by Parra et al.,79 hexagonal BN could be used to prevent the
biocorrosion of copper substrates by Escherichia coli. After
24 hours of incubation with BN coated copper sample, bacteria
viability came up to 118%, indicating that not only the BN
itself does not seem to have any inherent antibacterial ability,
but also that it would prevent harming copper ions to interact
with the bacteria deposited on the surface. The result is inter-
esting, especially considering that bacterial adhesion results
enhanced in the case of hexagonal BN coating with respect to
the untreated substrate. A study80 shows that when boron (NaB
is the source) was integrated with graphene oxide, there is an
enhancement is cell attachment and proliferation. It would be
worth investigating whether the BN itself is required for this
eﬀect, or any other boron source could also enhance the cell
proliferation.
Conclusion
Here we propose that BN could be an interesting alternative to
graphene-based materials when it comes to bio-applications.
Table 1 sums up all the studies reported on BN biocompatibi-
lity. Table 280–88 presents the findings from some key studies
on biocompatibility of graphene-based materials. Overall,
these studies have been performed with similar concentrations
and exposure times, and they suggest that BN biocompatibility
is comparable to that of carbon-based 2D materials.
Nevertheless, more is needed to be done to characterize the
impact of these 2D materials on/in living systems. Diﬀerent
forms of BN and carbon-based 2D materials diﬀer consider-
ably in processing methods, the degree of material purity, its
size, shape and thickness of structure. Moreover, in case of
BN, the use of various coatings and surface treatments makes
it harder to compare the studies and identify equivocal
thresholds for time of exposure and maximum doses. It
should be noted that similar material processing and mor-
phology cannot be expected to deliver the same results on all
Table 2 Correlation between the type of graphene, concentration and time of exposure on diﬀerent bacteria/mammalian cells and their responses
Graphene form Cell type
Max concentration of
exposure (μg ml−1)
Time of
exposure (hours) Result Ref.
GO/rGO E. coli 40 2 Antibacterial 81
GO/rGO E. coli (DH5α) 85 2 Antibacterial 82
GO E. coli 75 16 Biocompatible 83
GO Mouse embryo fibroblasts 3T3 1 48 Biocompatible 84
GO HeLa cells 10 48 Biocompatible 85
GO Human lymphoblastic leukemia
MCF7-human breast cancer
10 24 Biocompatible 86
GO Human adipose stem cells 0.024% 24 Biocompatible 80
Pristine graphene monolayer L929 fibroblasts — 48 Biocompatible 87
Graphene film doped
with Ag nanoparticles
E. coli and mouse osteoblast-like
MC3T3-E1 cells
148 mg of AgNO3 which
corresponds to the mass
ration of graphene
24/7 days Antibacterial/
biocompatible
88
Review Biomaterials Science
2308 | Biomater. Sci., 2018, 6, 2298–2311 This journal is © The Royal Society of Chemistry 2018
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
cells lines, given the cellular specialization. Though the litera-
ture that is presented here reveals some overall contradictory
results, it has to be noted that this contradiction is coming
from the coatings/surfactants that are used along with BN but
not from pristine BN itself. Unlike other carbon nanomaterials
where the flake size, preparation method, shape and working
conditions play an important role in determining the toxicity
or bio-compatibility, the pristine forms of BN without coatings
turn out to be bio-compatible in vitro and in vivo. This can
project BN as a baseline 2D material for bio-applications and
once the clinical guidelines get defined for the most relevant
biocompatibility parameters, diﬀerent strategies can be
adopted to engineer the BN nanostructures for specific appli-
cations like imaging, drug delivery and stimulation.
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